Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
$0.00
$0.00
$0.00
N/A1.86200 shsN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$0.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
Motif Bio Plc stock logo
MTFB
Motif Bio
$0.11
$0.10
$0.08
$11.50
N/AN/AN/A867,698 shs
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
$0.08
$0.08
$0.05
$0.35
N/A26.39N/AN/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Motif Bio Plc stock logo
MTFB
Motif Bio
0.00%0.00%0.00%0.00%0.00%
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
0.00%0.00%0.00%0.00%+79,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Motif Bio Plc stock logo
MTFB
Motif Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
0.00
N/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00
N/AN/AN/A
Motif Bio Plc stock logo
MTFB
Motif Bio
0.00
N/AN/AN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
Motif Bio Plc stock logo
MTFB
Motif Bio
N/AN/AN/AN/AN/AN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
Motif Bio Plc stock logo
MTFB
Motif Bio
N/AN/A0.00N/AN/AN/AN/AN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
Motif Bio Plc stock logo
MTFB
Motif Bio
N/AN/AN/AN/AN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
Motif Bio Plc stock logo
MTFB
Motif Bio
N/AN/AN/A
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
20N/AN/ANot Optionable
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
Motif Bio Plc stock logo
MTFB
Motif Bio
7N/AN/ANot Optionable
Parnell Pharmaceuticals Holdings Ltd stock logo
PARNF
Parnell Pharmaceuticals
51N/AN/ANot Optionable

Recent News About These Companies

Parnell Pharmaceuticals Holdings Ltd.
The Birth Parent Experience
Parental mental health and parent wellbeing
Parnell Pharmaceuticals Holdings Ltd (PARNF)
The best Netflix original movies right now
Schooling tips for parents of autistic children
How Parents Harm Their Children

Media Sentiment Over Time

Anthera Pharmaceuticals stock logo

Anthera Pharmaceuticals OTCMKTS:ANTH

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Innovus Pharmaceuticals stock logo

Innovus Pharmaceuticals OTCMKTS:INNVD

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Motif Bio stock logo

Motif Bio NASDAQ:MTFB

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Parnell Pharmaceuticals stock logo

Parnell Pharmaceuticals OTCMKTS:PARNF

$0.08 0.00 (0.00%)
As of 04/22/2025

Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.